Nikolaou Marinos, Kourea Helen P, Tzelepi Vasiliki, Adonakis Georgios, Scopa Chrisoula D, Tsapanos Vasilios, Kardamakis Dimitrios, Kalofonos Charalambos, Decavalas Georgios
Department of Obstetrics-Gynecology, University of Patras, Medical School, Patras, Greece.
J BUON. 2014 Jan-Mar;19(1):198-202.
Previous studies have shown that elevated preoperative serum CA 125 levels strongly correlate with various clinical and pathological variables and prognosis of patients with endometrial carcinoma (EC). The aim of the present study was to evaluate the clinical significance of preoperative serum CA 125 levels in patients with EC.
A retrospective study of all EC patients treated at our institution between 1995 and 2010 with available follow-up was conducted. The preoperative serum level of CA 125 was measured in 99 patients and evaluated in relation to various clinical and pathological variables and outcome. We used the cut-off level of 20 U/ml for CA 125 on chi-square test for categorical variables. Survival analysis was performed with the use of Kaplan Meier method, the log rank test and Cox proportional hazards regression analysis.
In the early stages of disease the mean values of CA 125 were 35 U/ml (SD±70) for stages IA-IB and 21 U/ml (SD±29) for stage IC (Mann-Whitney test for continuous variables). In advanced stages of disease (III-IV), the values of preoperative serum CA 125 levels were statistically increased, with mean value 54 U/ml (SD±44), in comparison to stages IA-IB (p=0.02) and IC (p=0.007). According to the multivariate analysis, elevated preoperative serum CA 125 level (p=0.043) and histological tumor type (p=0.004) were independent prognostic factors for disease free survival (DFS) and overall survival (OS) of patients with EC.
The current study suggests that measurement of preoperative serum CA 125 is a useful clinical tool in the prognosis of patients with EC.
既往研究表明，术前血清CA 125水平升高与子宫内膜癌（EC）患者的各种临床和病理变量及预后密切相关。本研究的目的是评估术前血清CA 125水平在EC患者中的临床意义。
对1995年至2010年在本机构接受治疗且有随访资料的所有EC患者进行回顾性研究。测定了99例患者术前血清CA 125水平，并评估其与各种临床和病理变量及结局的关系。对于分类变量，我们在卡方检验中使用CA 125的临界值为20 U/ml。采用Kaplan-Meier法、对数秩检验和Cox比例风险回归分析进行生存分析。
在疾病早期，IA-IB期CA 125的平均值为35 U/ml（标准差±70），IC期为21 U/ml（标准差±29）（连续变量采用Mann-Whitney检验）。在疾病晚期（III-IV期），术前血清CA 125水平值在统计学上升高，平均值为54 U/ml（标准差±44），与IA-IB期（p=0.02）和IC期（p=0.007）相比。根据多变量分析，术前血清CA 125水平升高（p=0.043）和组织学肿瘤类型（p=0.004）是EC患者无病生存期（DFS）和总生存期（OS）的独立预后因素。
本研究表明，术前血清CA 125的测定是评估EC患者预后的一种有用的临床工具。
